

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

**POLL RESULTS OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING HELD ON 31 JULY 2024**

The Company is pleased to announce that the resolution set out in the notice of EGM and proposed at the EGM was duly passed by the Shareholders by way of poll at the EGM.

References are made to the notice of the 2024 first extraordinary general meeting (“**EGM**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) dated 12 July 2024 and the circular of the Company of even date (the “**Circular**”) in relation to, among other things, the continuing connected transactions contemplated under the Supplemental Sales Framework Agreement and the EGM. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Board is pleased to announce the poll results in respect of the resolution proposed at the EGM as follows:

Ordinary Resolution proposed at the EGM		Number of Votes (%)	
		For	Against
1.	“ <b>THAT</b> (a) the Supplemental Sales Framework Agreement to the Existing Sales Framework Agreement, a copy of which is tabled at the meeting and marked “A” and initialed by the chairman of the meeting for identification purpose, the terms thereof and the transactions and the Annual Caps contemplated thereunder be and are hereby approved, ratified and confirmed; and (b) any one Director be and is hereby authorized for and on behalf of the Company to execute, deliver and/or affix seal on all such other documents, instruments and agreements and to do all such acts or things deemed by him/her to be incidental to, ancillary to or in connection with the matters contemplated in the Sales Framework Agreement.”	1,645,827,621 (100%)	0 (0%)
The resolution was duly passed as an ordinary resolution.			

As at the date of the EGM, the total number of issued and fully paid up shares of the Company was 6,282,510,461 Shares. As disclosed in the Circular, CRH (Pharmaceutical) Limited and Commotra Company Limited, which are wholly-owned subsidiaries of CR Holdings, are directly interested in 3,354,786,612 Shares, representing approximately 53.40% of the issued share capital of the Company. CR Holdings is a controlling shareholder of each of the Company and CR Healthcare, and is therefore considered to have a material interest in the Supplemental Sales Framework Agreement and the transactions and the Annual Caps contemplated thereunder. Accordingly, CR Holdings and its associates were required to abstain, and had abstained, from voting on the resolution proposed at the EGM. Therefore, the total number of Shares entitling the Shareholders to attend and vote for or against the resolution proposed at the EGM was 2,927,723,849 Shares.

Save as disclosed above, there were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolution proposed at the EGM as set out in Rule 13.40 of the Listing Rules, and there were no Shares requiring the Shareholders to abstain from voting at the EGM under the Listing Rules. No Shareholders had stated their intention in the Circular to vote against or to abstain from voting on the resolution proposed at the EGM.

The EGM was chaired by Mr. Han Yuewei, the chairman of the Board of the Company. The Directors, Mdm. Deng Rong, Mdm. Guo Wei, Mr. Sun Yongqiang, Mdm. Jiao Ruifang, Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun and Mr. Fu Tingmei attended the EGM in person or via video conference, whilst Mr. Bai Xiaosong, Mr. Tao Ran, Mr. Guo Chuan and Mr. Zhang Kejian were unable to attend the EGM due to their other business commitments.

Tricor Investor Services Limited, the share registrar of the Company, acted as scrutineers for the vote-taking at the EGM.

Shareholders may refer to the Circular for details of the above resolution proposed at the EGM. The Circular may be viewed and downloaded from the Company's website at [www.crpharm.com](http://www.crpharm.com) or the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).

By order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Han Yuewei**  
*Chairman*

Hong Kong, 31 July 2024

*As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*